Literature DB >> 19101757

Successful treatment for sympathetic storms in a patient with neuro-Behçet's disease.

Takahisa Gono1, Megumi Murata, Yasushi Kawaguchi, Daisuke Wakasugi, Makoto Soejima, Hisashi Yamanaka, Masako Hara.   

Abstract

Sympathetic storms (SyS) are characterized by hyperactivity of autonomic functions, resulting in episodes of hyperthermia, hypertension, tachycardia, and hyperhidrosis. We show here a patient with neuro-Behçet's disease (NBD) complicated by SyS. Although SyS is well known to occur with brain tumors, trauma, and hydrocephalus, this is the first report to show that SyS is a manifestation of central nervous system involvement in a patient with NBD. High concentrations of norepinephrine (NE) and IL-8 in cerebrospinal fluid reflected the activity of SyS. The patient's symptoms showed almost complete improvement after treatment with corticosteroids and intravenous cyclophosphamide. Also, the concentrations of NE and IL-8 were decreased to normal levels. An awareness of the potential for SyS and adequate immunosuppressant therapy are of importance when dealing with patients with NBD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19101757     DOI: 10.1007/s10067-008-1070-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  8 in total

1.  Blood-brain barrier for adrenaline.

Authors:  H WEIL-MALHERBE; J AXELROD; R TOMCHICK
Journal:  Science       Date:  1959-05-01       Impact factor: 47.728

2.  Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group.

Authors:  G Akman-Demir; P Serdaroglu; B Tasçi
Journal:  Brain       Date:  1999-11       Impact factor: 13.501

Review 3.  Sympathetic storms in a child with a midbrain glioma: a variant of diencephalic seizures.

Authors:  K Y Goh; E J Conway; R C DaRosso; C A Muszynski; F J Epstein
Journal:  Pediatr Neurol       Date:  1999-10       Impact factor: 3.372

Review 4.  The sympathetic nervous system: the muse of primary hypertension.

Authors:  V DeQuattro; M Feng
Journal:  J Hum Hypertens       Date:  2002-03       Impact factor: 3.012

5.  Effects of Alzheimer's disease severity on cerebrospinal fluid norepinephrine concentration.

Authors:  R Elrod; E R Peskind; L DiGiacomo; K I Brodkin; R C Veith; M A Raskind
Journal:  Am J Psychiatry       Date:  1997-01       Impact factor: 18.112

6.  Serum interleukin-8 as a serologic marker of activity in Behçet's disease.

Authors:  Güneş Gür-Toy; Nurdan Lenk; Basak Yalcin; Sabahat Aksaray; Nuran Alli
Journal:  Int J Dermatol       Date:  2005-08       Impact factor: 2.736

7.  Longitudinal analysis of cytokines and chemokines in the cerebrospinal fluid of a patient with Neuro-Sweet disease presenting with recurrent encephalomeningitis.

Authors:  Akio Kimura; Takeo Sakurai; Akihiro Koumura; Yoshihiro Suzuki; Yuji Tanaka; Isao Hozumi; Hideto Nakajima; Takashi Ichiyama; Takashi Inuzuka
Journal:  Intern Med       Date:  2008-02-01       Impact factor: 1.271

8.  Enhanced interleukin 8 secretion in circulation of patients with Behçet's disease.

Authors:  A al-Dalaan; S al-Sedairy; S al-Balaa; M al-Janadi; K Elramahi; S Bahabri; S Siddiqui
Journal:  J Rheumatol       Date:  1995-05       Impact factor: 4.666

  8 in total
  3 in total

Review 1.  Evaluation of current therapeutic strategies in Behçet's disease.

Authors:  Iliana Alexoudi; Violetta Kapsimali; Aristides Vaiopoulos; Meletios Kanakis; George Vaiopoulos
Journal:  Clin Rheumatol       Date:  2010-09-15       Impact factor: 2.980

2.  Serum IL-4, IL-12, IL-13, IL-27, and IL-33 levels in active and inactive ocular Behcet's disease.

Authors:  Abdullah Kursat Cingu; Fatih Mehmet Turkcu; Serdar Aktas; Alparslan Sahin; Orhan Ayyildiz
Journal:  Int Ophthalmol       Date:  2020-07-29       Impact factor: 2.031

3.  Behçet's Disease with Severe Autonomic Disorders Developing after Herpes Zoster.

Authors:  Serina Koto; Masataka Umeda; Hiroaki Kawano; Yushiro Endo; Toshimasa Shimizu; Tomohiro Koga; Kunihiro Ichinose; Hideki Nakamura; Akihiro Mukaino; Osamu Higuchi; Shunya Nakane; Atsushi Kawakami
Journal:  Intern Med       Date:  2020-02-01       Impact factor: 1.271

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.